The hematopoietic stem cell regulatory gene latexin has tumor-suppressive properties in malignant melanoma

Journal of Investigative Dermatology

Volumn 133, Issue 7, 2013, Pages 1827-1833

  Muthusamy, Viswanathan ^a   Premi, Sanjay ^a   Soper, Cara ^b   Platt, James ^a   Bosenberg, Marcus ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Champlain Valley Physicians Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; KRUPPEL LIKE FACTOR 4; LATEXIN; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; GENE SILENCING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LATEXIN GENE; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NEVUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; TUMOR CELL; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84879415678     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.48     Document Type: Article

References (46)

1. Aagaard A, Listwan P, Cowieson N et al. (2005) An inflammatory role for the mammalian carboxypeptidase inhibitor latexin: relationship to cystatins and the tumor suppressor TIG1. Structure 13:309-17 (Pubitemid 40247706)
2. Aitken J, Welch J, Duffy D et al. (1999) CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 91:446-52 (Pubitemid 29128281)
3. Arimatsu Y (1994) Latexin: a molecular marker for regional specification in the neocortex. Neurosci Res 20:131-5 (Pubitemid 24273618)
4. Avery-Kiejda KA, Bowden NA, Croft AJ et al. (2011) P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer 11:203
5. Bai WZ, Ishida M, Arimatsu Y (2004) Chemically defined feedback connections from infragranular layers of sensory association cortices in the rat. Neuroscience 123:257-67 (Pubitemid 37518493)
6. Berger MF, Hodis E, Heffernan TP et al. (2012) Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485:502-6
7. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-7 (Pubitemid 27298715)
8. Chambers I, Colby D, Robertson M et al. (2003) Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113:643-55 (Pubitemid 36694189)
9. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54 (Pubitemid 34716871)
10. Edlundh-Rose E, Egyhazi S, Omholt K et al. (2006) NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16:471-8 (Pubitemid 44934704)
11. Fang D, Nguyen TK, Leishear K et al. (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328-37 (Pubitemid 41508000)
12. Galli R, Binda E, Orfanelli U et al. (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64:7011-21 (Pubitemid 39331011)
13. Goldstein AM, Chan M, Harland M et al. (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44:99-106
14. 0-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 12:4619-27 (Pubitemid 44297813)
15. Guan X, Sagara J, Yokoyama T et al. (2003) ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma. Int J Cancer 107:202-8 (Pubitemid 37152898)
16. Hatanaka Y, Uratani Y, Takiguchi-Hayashi K et al. (1994) Intracortical regionality represented by specific transcription for a novel protein, latexin. Eur J Neurosci 6:973-82 (Pubitemid 24185321)
17. Herman JG, Graff JR, Myohanen S et al. (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-6 (Pubitemid 26296693)
18. Hodis E, Watson IR, Kryukov GV et al. (2012) A landscape of driver mutations in melanoma. Cell 150:251-63
19. Hoek K, Rimm DL, Williams KR et al. (2004) Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64:5270-82 (Pubitemid 39006547)
20. Hoon DS, Spugnardi M, Kuo C et al. (2004) Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23:4014-22 (Pubitemid 38747930)
21. Jin M, Ishida M, Katoh-Fukui Y et al. (2006) Reduced pain sensitivity in mice lacking latexin, an inhibitor of metallocarboxypeptidases. Brain Res 1075:117-21
22. Jing C, El-Ghany MA, Beesley C et al. (2002) Tazarotene-induced gene 1 (TIG1) expression in prostate carcinomas and its relationship to tumor-igenicity. J Natl Cancer Inst 94:482-90 (Pubitemid 34411286)
23. Kashani-Sabet M, Rangel J, Torabian S et al. (2009) A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci USA 106:6268-72
24. Koga Y, Pelizzola M, Cheng E et al. (2009) Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 19:1462-70
25. Krauthammer M, Kong Y, Ha BH et al. (2012) Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44:1006-14
26. Lapidot T, Sirard C, Vormoor J et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-8 (Pubitemid 24067706)
27. Li Y, Basang Z, Ding H et al. (2011) Latexin expression is downregulated in human gastric carcinomas and exhibits tumor suppressor potential. BMC Cancer 11:121
28. Liang Y, Jansen M, Aronow B et al. (2007) The quantitative trait gene latexin influences the size of the hematopoietic stem cell population in mice. Nat Genet 39:178-88 (Pubitemid 46184348)
29. Liang Y, Van Zant G (2008) Aging stem cells, latexin, and longevity. Exp Cell Res 314:1962-72
30. Liu Q, Yu L, Gao J et al. (2000) Cloning, tissue expression pattern and genomic organization of latexin, a human homologue of rat carboxypeptidase A inhibitor. Mol Biol Rep 27:241-6 (Pubitemid 32608414)
31. Liu Y, Howard D, Rector K et al. (2012) Latexin is down-regulated in hematopoietic malignancies and restoration of expression inhibits lymphoma growth. PLoS One 7:e44979
32. Lobo NA, Shimono Y, Qian D et al. (2007) The biology of cancer stem cells. Annu Rev Cell Dev Biol 23:675-99
33. Loh YH, Wu Q, Chew JL et al. (2006) The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 38:431-40
34. Muthusamy V, Duraisamy S, Bradbury CM et al. (2006) Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 66:11187-93 (Pubitemid 46009946)
35. Nichols J, Zevnik B, Anastassiadis K et al. (1998) Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor. Cell 95:379-91 (Pubitemid 28507326)
36. Nikolaev SI, Rimoldi D, Iseli C et al. (2012) Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44:133-9
37. Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent induced pluripotent stem cells. Nature 448:313-7 (Pubitemid 47080336)
38. Pallares I, Bonet R, Garcia-Castellanos R et al. (2005) Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin. Proc Natl Acad Sci USA 102:3978-83 (Pubitemid 40388541)
39. Spugnardi M, Tommasi S, Dammann R et al. (2003) Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 63:1639-43 (Pubitemid 36373656)
40. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-76 (Pubitemid 44233629)
41. Talantov D, Mazumder A, Yu JX et al. (2005) Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11:7234-42 (Pubitemid 41507680)
42. Tawbi HA, Beumer JH, Tarhini AA et al. (2012) Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol; e-pub ahead of print 21 November 2012
43. Wei X, Walia V, Lin JC et al. (2011) Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43:442-6
44. Wernig M, Meissner A, Foreman R et al. (2007) In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448:318-24 (Pubitemid 47080337)
45. Youssef EM, Chen XQ, Higuchi E et al. (2004) Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res 64:2411-7 (Pubitemid 38523894)
46. Zhang G, Li G (2012) Novel multiple markers to distinguish melanoma from dysplastic nevi. PLoS One 7:e45037